- Home
- UPXI vs LIXT Comparison
UPXI vs LIXT Comparison
Compare UPXI & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UPXI
- LIXT
- Stock Information
- Founded
- UPXI 2018
- LIXT 2005
- Country
- UPXI United States
- LIXT United States
- Employees
- UPXI N/A
- LIXT N/A
- Industry
- UPXI Medicinal Chemicals and Botanical Products
- LIXT Biotechnology: Pharmaceutical Preparations
- Sector
- UPXI Health Care
- LIXT Health Care
- Exchange
- UPXI Nasdaq
- LIXT Nasdaq
- Market Cap
- UPXI 3.9M
- LIXT 4.1M
- IPO Year
- UPXI 2021
- LIXT N/A
- Fundamental
- Price
- UPXI $3.46
- LIXT $2.33
- Analyst Decision
- UPXI Hold
- LIXT
- Analyst Count
- UPXI 1
- LIXT 0
- Target Price
- UPXI $25.00
- LIXT N/A
- AVG Volume (30 Days)
- UPXI 50.7K
- LIXT 18.9K
- Earning Date
- UPXI 02-12-2025
- LIXT 11-12-2024
- Dividend Yield
- UPXI N/A
- LIXT N/A
- EPS Growth
- UPXI N/A
- LIXT N/A
- EPS
- UPXI N/A
- LIXT N/A
- Revenue
- UPXI $22,082,477.00
- LIXT N/A
- Revenue This Year
- UPXI $299.03
- LIXT N/A
- Revenue Next Year
- UPXI N/A
- LIXT N/A
- P/E Ratio
- UPXI N/A
- LIXT N/A
- Revenue Growth
- UPXI N/A
- LIXT N/A
- 52 Week Low
- UPXI $2.17
- LIXT $1.31
- 52 Week High
- UPXI $33.00
- LIXT $4.40
- Technical
- Relative Strength Index (RSI)
- UPXI 39.66
- LIXT 54.46
- Support Level
- UPXI $3.31
- LIXT $2.25
- Resistance Level
- UPXI $4.10
- LIXT $2.68
- Average True Range (ATR)
- UPXI 0.41
- LIXT 0.23
- MACD
- UPXI -0.04
- LIXT 0.01
- Stochastic Oscillator
- UPXI 9.38
- LIXT 53.90
About UPXI Upexi Inc.
Upexi Inc specializes in the development, manufacturing, and distribution of consumer products. It reaches consumers through its direct-to-consumer network, wholesale partnerships, and prominent third-party platforms like Amazon.
About LIXT Lixte Biotechnology Holdings Inc.
Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.